PETA Statement: Alzheimer’s Drug

For Immediate Release:
June 14, 2018

Tasgola Bruner 202-483-7382

Norfolk, Va. – Statement from PETA research associate and neuroscientist Emily Trunnell, Ph.D., regarding the ending of late-stage trials for Eli Lilly and AstraZeneca’s Alzheimer’s disease drug:

The failure rate in humans for new Alzheimer’s drugs now stands at a staggering 99.6 percent, and it’s well past time for experimenters to get the message: Stop wasting time on animal tests. For many years, they have tormented monkeys, mice, dogs, and other animals in an effort to create drugs to treat this devastating disease. Since animals don’t get human Alzheimer’s disease, experimenters manipulate their genomes in order to force the buildup of amyloid plaques similar to those in the brains of humans with the disease. The results, after decades of tests, include more than 100 failed drugs, an untold number of animal deaths, and the continued suffering of human victims of the disease.

For more information, please visit

For Media: Contact PETA's
Media Response Team.


Get PETA Updates

Stay up to date on the latest vegan trends and get breaking animal rights news delivered straight to your inbox!

By submitting this form, you’re acknowledging that you have read and agree to our privacy policy and agree to receive e-mails from us.

 Ingrid E. Newkirk

“Almost all of us grew up eating meat, wearing leather, and going to circuses and zoos. We never considered the impact of these actions on the animals involved. For whatever reason, you are now asking the question: Why should animals have rights?” READ MORE

— Ingrid E. Newkirk, PETA President and co-author of Animalkind